Your provider may suggest moving toward 2.4 mg , the full maintenance dose, over the coming weeks
(2023) The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial
Discussion In this study, we report arginine methylation at R76 as a novel PTM of GLUD1, which shields it from ubiquitin-dependent proteolysis
It was initially postulated to be a compensatory mechanism to the blood pressure lowering effect of GLP-1 RAs that was possibly mediated by their vasodilatory effect [9, 31] and/or increased urinary sodium excretion [32]
Start with the lowest prescribed dose
Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, et al